Evidence map›Paper›PMID 39650601›Full record

ArticleArXiv2024

High-throughput antibody screening with high-quality factor nanophotonics and bioprinting.

Sajjad Abdollahramezani, Darrell Omo-Lamai, Gerlof Bosman, Omid Hemmatyar, Sahil Dagli, Varun Dolia, Kai Chang, Nicholas A Güsken, Hamish Carr Delgado, Geert-Jan Boons and 5 more

Abstract readPreprint
PubMed Full text at PMC
In one paragraph

Article in ArXiv, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sajjad AbdollahramezaniDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Darrell Omo-LamaiDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Gerlof BosmanDepartment of Chemical Biology and Drug Discovery, Utrecht University, Utrecht, Netherlands.
Omid HemmatyarDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Sahil DagliDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Varun DoliaDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Kai ChangDepartment of Electrical Engineering, Stanford University, Stanford, CA, USA.
Nicholas A GüskenGeballe Laboratory for Advanced Materials, Stanford University, Stanford University, Stanford, CA, USA.
Hamish Carr DelgadoDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Geert-Jan BoonsDepartment of Chemical Biology and Drug Discovery, Utrecht University, Utrecht, Netherlands.
Mark L BrongersmaGeballe Laboratory for Advanced Materials, Stanford University, Stanford University, Stanford, CA, USA.
Fareeha SafirPumpkinseed Technologies, Palo Alto, CA, Stanford.
Butrus T Khuri-YakubDepartment of Electrical Engineering, Stanford University, Stanford, CA, USA.
Parivash MoradifarDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Jennifer DionneDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.

Funding

Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactionsR01AI165692 · NIAID · UNIVERSITY OF GEORGIA · PI BOONS, GEERT-JAN · 2022 to 2025
$2.2M
NIAID NIH HHS R01 AI165692
6 · The paper itself

Abstract

Empirical investigation of the quintillion-scale, functionally diverse antibody repertoires that can be generated synthetically or naturally is critical for identifying potential biotherapeutic leads, yet remains burdensome. We present high-throughput nanophotonics- and bioprinter-enabled screening (HT-NaBS), a multiplexed assay for large-scale, sample-efficient, and rapid characterization of antibody libraries. Our platform is built upon independently addressable pixelated nanoantennas exhibiting wavelength-scale mode volumes, high-quality factors (high-Q) exceeding 5000, and pattern densities exceeding one million sensors per square centimeter. Our custom-built acoustic bioprinter enables individual sensor functionalization via the deposition of picoliter droplets from a library of capture antigens at rates up to 25,000 droplets per second. We detect subtle differentiation in the target binding signature through spatially-resolved spectral imaging of hundreds of resonators simultaneously, elucidating antigen-antibody binding kinetic rates, affinity constant, and specificity. We demonstrate HT-NaBS on a panel of antibodies targeting SARS-CoV-2, Influenza A, and Influenza B antigens, with a sub-picomolar limit of detection within 30 minutes. Furthermore, through epitope binning analysis, we demonstrate the competence and diversity of a library of native antibodies targeting functional epitopes on a priority pathogen (H5N1 bird flu) and on glycosylated therapeutic Cetuximab antibodies against epidermal growth factor receptor. With a roadmap to image tens of thousands of sensors simultaneously, this high-throughput, resource-efficient, and label-free platform can rapidly screen for high-affinity and broad epitope coverage, accelerating biotherapeutic discovery and

Identifiers

PMID39650601
PMCPMC11623700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.